Characterization/NN
of/IN
a/DT
mutant/JJ
cell/NN
line/NN
that/WDT
does/VBZ
not/RB
activate/VB
NF-kappaB/NN
in/IN
response/NN
to/TO
multiple/JJ
stimuli/NNS
./.

Numerous/JJ
genes/NNS
required/VBN
during/IN
the/DT
immune/JJ
or/CC
inflammation/NN
response/NN
as/RB
well/RB
as/IN
the/DT
adhesion/NN
process/NN
are/VBP
regulated/VBN
by/IN
nuclear/JJ
factor/NN
kappaB/NN
(/(
NF-kappaB/NN
)/)
./.
=====
Associated/VBN
with/IN
its/PRP$
inhibitor/NN
,/,
I/NN
kappaB/NN
,/,
NF-kappaB/NN
resides/VBZ
as/IN
an/DT
inactive/JJ
form/NN
in/IN
the/DT
cytoplasm/NN
./.
=====
Upon/IN
stimulation/NN
by/IN
various/JJ
agents/NNS
,/,
I/NN
kappaB/NN
is/VBZ
proteolyzed/VBN
and/CC
NF-kappaB/NN
translocates/VBZ
to/TO
the/DT
nucleus/NN
,/,
where/WRB
it/PRP
activates/VBZ
its/PRP$
target/NN
genes/NNS
./.
=====
The/DT
transduction/NN
pathways/NNS
that/WDT
lead/VBP
to/TO
I/NN
kappaB/NN
inactivation/NN
remain/VBP
poorly/RB
understood/VBN
./.
=====
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
characterized/VBN
a/DT
cellular/JJ
mutant/NN
,/,
the/DT
70/Z3-derived/JJ
1.3E2/NN
murine/JJ
pre-B/JJ
cell/NN
line/NN
,/,
that/WDT
does/VBZ
not/RB
activate/VB
NF-kappaB/NN
in/IN
response/NN
to/TO
several/JJ
stimuli/NNS
./.
=====
We/PRP
demonstrate/VBP
that/IN
upon/IN
stimulation/NN
by/IN
lipopolysaccharide/NN
,/,
Taxol/NN
,/,
phorbol/NN
myristate/NN
acetate/NN
,/,
interleukin-1/NN
,/,
or/CC
double-stranded/JJ
RNA/NN
,/,
I/NN
kappaB/NN
alpha/NN
is/VBZ
not/RB
degraded/VBN
,/,
as/IN
a/DT
result/NN
of/IN
an/DT
absence/NN
of/IN
induced/VBN
phosphorylation/NN
on/IN
serines/NNS
32/CD
and/CC
36/CD
./.
=====
Neither/CC
a/DT
mutation/NN
in/IN
I/NN
kappaB/NN
alpha/NN
nor/CC
a/DT
mutation/NN
in/IN
p50/NN
or/CC
relA/NN
,/,
the/DT
two/CD
major/JJ
subunits/NNS
of/IN
NF-kappaB/NN
in/IN
this/DT
cell/NN
line/NN
,/,
accounts/VBZ
for/IN
this/DT
phosphorylation/NN
defect/NN
./.
=====
As/RB
well/RB
as/IN
culminating/VBG
in/IN
the/DT
inducible/JJ
phosphorylation/NN
of/IN
I/NN
kappaB/NN
alpha/NN
on/IN
serines/NNS
32/CD
and/CC
36/CD
,/,
all/PDT
the/DT
stimuli/NNS
that/WDT
are/VBP
inactive/JJ
on/IN
1.3E2/NN
cells/NNS
exhibit/VBP
a/DT
sensitivity/NN
to/TO
the/DT
antioxidant/JJ
pyrrolidine/NN
dithiocarbamate/NN
(/(
PDTC/NN
)/)
./.
=====
In/IN
contrast/NN
,/,
stimuli/NNS
such/JJ
as/IN
hyperosmotic/JJ
shock/NN
or/CC
phosphatase/NN
inhibitors/NNS
,/,
which/WDT
use/VBP
PDTC-insensitive/JJ
pathways/NNS
,/,
induce/VBP
I/NN
kappaB/NN
alpha/NN
degradation/NN
in/IN
1.3E2/NN
./.
=====
Analysis/NN
of/IN
the/DT
redox/JJ
status/NN
of/IN
1.3E2/NN
does/VBZ
not/RB
reveal/VB
any/DT
difference/NN
from/IN
wild-type/JJ
70Z/3/NN
./.
=====
We/PRP
also/RB
report/VBP
that/IN
the/DT
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
1/CD
(/(
HTLV-1/NN
)/)
-derived/JJ
Tax/NN
trans-activator/NN
induces/VBZ
NF-kappaB/NN
activity/NN
in/IN
1.3E2/NN
,/,
suggesting/VBG
that/IN
this/DT
viral/JJ
protein/NN
does/VBZ
not/RB
operate/VB
via/IN
the/DT
defective/JJ
pathway/NN
./.
=====
Finally/RB
,/,
we/PRP
show/VBP
that/IN
two/CD
other/JJ
I/NN
kappaB/NN
molecules/NNS
,/,
I/NN
kappaB/NN
beta/NN
and/CC
the/DT
recently/RB
identified/VBN
I/NN
kappaB/NN
epsilon/NN
,/,
are/VBP
not/RB
degraded/VBN
in/IN
the/DT
1.3E2/NN
cell/NN
line/NN
following/VBG
stimulation/NN
./.
=====
Our/PRP$
results/NNS
demonstrate/VBP
that/IN
1.3E2/NN
is/VBZ
a/DT
cellular/JJ
transduction/NN
mutant/NN
exhibiting/VBG
a/DT
defect/NN
in/IN
a/DT
step/NN
that/WDT
is/VBZ
required/VBN
by/IN
several/JJ
different/JJ
stimuli/NNS
to/TO
activate/VB
NF-kappaB/NN
./.
=====
In/IN
addition/NN
,/,
this/DT
analysis/NN
suggests/VBZ
a/DT
common/JJ
step/NN
in/IN
the/DT
signaling/NN
pathways/NNS
that/WDT
trigger/VBP
I/NN
kappaB/NN
alpha/NN
,/,
I/NN
kappaB/NN
beta/NN
,/,
and/CC
I/NN
kappaB/NN
epsilon/NN
degradation/NN
./.